XNCR biotech catalysts & pipeline

XENCOR INC · Data as of 2026-10-25

Upcoming catalysts

obexelimab — NDA/BLA submission

H2 2026

Zenas announced that it submitted a BLA to the FDA for the treatment of IgG4-RD in May 2026 and anticipates submitting a Marketing Authorization Application to the European Medicines Agency in the second half of 2026.

Source filing

XmAb942 (Xtend TL1A) — Interim data

Late 2026

• Enrollment expectations support a XENITH-UC blinded interim analysis around year-end 2026 and reaching the primary endpoint of the 12-week induction period during the second half of 2027.

Source filing

XmAb412 — Initial data

H1 2027

And we recently started the Phase 1 study of XmAb412, our first XenLock™ bispecific antibody, and plan to have healthy participant data in the first half of 2027.

Source filing

XmAb541 (CLDN6 x CD3) — Interim data

in 2027

The Phase 1 dose-escalation study of XmAb541 and XmAb808 is ongoing and expected to reach the combination's target dose range in 2027.

Source filing

XmAb819 — Clinical data readout

H1 2027

Dose escalation of subcutaneous administration in advanced ccRCC is ongoing, with anticipated results during the first half of 2027.

Source filing

XmAb942 (Xtend TL1A) — Topline data

2H27

XmAb942 enrollment in XENITH-UC remains on track with primary endpoint of the 12-week induction period expected in 2H27

Source filing

XmAb541 (CLDN6 x CD3) — Conference presentation

2H26

• Present new clinical data to support a recommended Phase 3 dose in 2H26

Source filing

XmAb657 (CD19 x CD3) — Conference presentation

2H26

Xencor plans to provide an update on progress achieved in the Phase 1 study of XmAb657 in 2H26.

Source filing

XmAb819 — Conference presentation

Oct 23–Oct 27

XmAb819 ccRCC expansion cohorts to be presented in an oral session at ESMO 2026; multiple Phase 1 sub-studies in earlier lines of therapy and additional indications now open for enrollment or planned

Source filing

Explore the free biotech catalyst calendar